Monoclonal antibody therapy for COVID-19 during pregnancy
- Authors: Abdulganieva D.I.1,2, Dyakova E.V.2, Ivanova E.V.2, Shamsutdinova N.G.1, Yangurazova A.R.1, Nigmatullina N.A.2, Fatkullin I.F.1
-
Affiliations:
- Kazan State Medical University
- Republican Clinical Hospital, Kazan
- Issue: Vol 25, No 9 (2023): Otorhinolaryngology and pulmonology
- Pages: 577-580
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/253575
- DOI: https://doi.org/10.26442/20751753.2023.9.202395
- ID: 253575
Cite item
Full Text
Abstract
Aim. Pregnancy worsens COVID-19 and has been listed by the US Food and Drug Administration as a high risk factor for complicating COVID-19. The severe course of a new coronavirus infection in some pregnant patients has created the prerequisites for the search for treatment methods that can reduce the likelihood of adverse outcomes. One of these therapy options is treatment with virus-neutralizing antibodies – monoclonal antibodies. Experience with the use of monoclonal antibodies for the treatment of pregnant women is very limited, but in 2021 pregnancy was recognized as a high risk factor for the course of a new coronavirus infection, making it possible to use this group of drugs.
Materials and methods. We described the experience of COVID-19 monoclonal antibody therapy during pregnancy in the Republic of Tatarstan. A retrospective analysis of 18 case histories of pregnant patients with mild and moderate course of confirmed coronavirus infection, treated with monoclonal antibodies (casirivimab/imdevimab) from March 2022 to June 2022, was carried out on the basis of the Perinatal Center of the Republican Clinical Hospital, Kazan, Republic of Tatarstan.
Results. All patients tolerated the administration of casirivimab/imdevimab satisfactorily; no adverse drug reactions were identified. Subjective improvement was observed on the 3rd day of MCA treatment. Delivery through the natural birth canal was carried out on time in 11 women; by caesarean section on time – in 5 patients. A follow-up study of children born to 18 patients who had COVID-19 was collected. The age of the children at the time of information collection ranged from 10 months – 1 year 1 month. Currently, all children are healthy and developing according to their age.
Conclusion. In all pregnant patients with a new coronavirus infection with mild to moderate course, the administration of casirivimab/imdevimab was an effective method of treating the new coronavirus infection. The follow-up of children born from 18 patients was followed: the children’s condition was satisfactory, their development corresponded to their age.
Full Text
##article.viewOnOriginalSite##About the authors
Diana I. Abdulganieva
Kazan State Medical University; Republican Clinical Hospital, Kazan
Author for correspondence.
Email: diana_s@mail.ru
ORCID iD: 0000-0001-7069-2725
D. Sci. (Med.), Prof., Kazan State Medical University, Republican Clinical Hospital
Russian Federation, Kazan; KazanEkaterina V. Dyakova
Republican Clinical Hospital, Kazan
Email: vrkaty.dyakowa@yandex.ru
ORCID iD: 0000-0003-1366-006X
Pulmonologist, Republican Clinical Hospital
Russian Federation, KazanEra V. Ivanova
Republican Clinical Hospital, Kazan
Email: Ivanova.rkb@mail.ru
ORCID iD: 0009-0008-6907-8806
Obstetrician-Gynecologist, Republican Clinical Hospital
Russian Federation, KazanNailya G. Shamsutdinova
Kazan State Medical University
Email: ngshamsutdinova@gmail.com
ORCID iD: 0000-0001-7320-0861
Cand. Sci. (Med.), Kazan State Medical University
Russian Federation, KazanAsiya R. Yangurazova
Kazan State Medical University
Email: yaasirah8@gmail.com
ORCID iD: 0009-0002-1508-0931
Resident of the Department, Kazan State Medical University
Russian Federation, KazanNigina A. Nigmatullina
Republican Clinical Hospital, Kazan
Email: nigi76na@rambler.ru
ORCID iD: 0000-0003-4441-8858
Cand. Sci. (Med.), Republican Clinical Hospital
Russian Federation, KazanIldar F. Fatkullin
Kazan State Medical University
Email: Krd1@mail.ru
ORCID iD: 0000-0001-9673-9077
D. Sci. (Med.), Prof., Kazan State Medical University
Russian Federation, KazanReferences
- Доброхотова Ю.Э., Гуменюк Л.Н., Пучкина Г.А., Михайличенко В.Ю. Осложнения и исходы беременности у женщин с COVID-19. Акушерство и гинекология. 2022;3:32-8 [Dobrokhotova IuE, Gumeniuk LN, Puchkina GA, Mikhaylichenko VIu. Oslozhneniia i iskhody beremennosti u zhenshchin s COVID-19. Akusherstvo i ginekologiia. 2022;3:32-8 (in Russian)]. doi: 10.18565/aig.2022.3.32-38
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 17. М., 2022; c. 5 [Vremennyie metodicheskiie rekomendatsii “Profilaktika, diagnostika i lecheniie novoi koronavirusnoi infektsii (COVID-19)”. Versiia 17. Mosow, 2022; p. 5 (in Russian)].
- Драпкина О.М., Авдеев С.Н., Брико Н.И., и др. Вакцинация в период пандемии СOVID-19. Методические рекомендации. М.: Силицея-Полиграф, 2022 [Drapkina OM, Avdeiev SN, Briko NI, et al. Vaktsinatsiia v period pandemii SOVID-19. Metodicheskiie rekomendatsii. Mosow: Silitseia-Poligraf, 2022 (in Russian)].
- Методические рекомендации «Организация оказания медицинской помощи беременным, роженицам, родильницам и новорожденным при новой коронавирусной инфекции COVID-19». Версия 4. М., 2022; с. 5 [Metodicheskiie rekomendatsii “Organizatsiia okazaniia meditsinskoi pomoshchi beremennym, rozhenitsam, rodil'nitsam i novorozhdennym pri novoi koronavirusnoi infektsii COVID-19”. Versiia 4. Mosow, 2022; p. 5 (in Russian)].
- Folkman R, Blennow O, Tovatt T, et al. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection. 2023;51:261-3. doi: 10.1007/s15010-022-01829-4
- Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nature. 2021;21:382-93.
- Hirshberg JS, Cooke E, Oakes MC, et al. Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report. Am J Obstet Gynecol. 2021;225(6):688-9. doi: 10.1016/j.ajog.2021.08.025
- Chang MH, Cowman K, Guo Y, et al. A real-world assessment of tolerability and treatment outcomes of COVID-19 monoclonal antibodies administered in pregrancy. Am J Obstet Gynecol. 2022;226(5):743-5. doi: 10.1016/j.ajog.2022.01.018
- Thilagar BP, Ghosh AK, Nguyen J, et al. GhoshOutcomes of Anti-Spike Monoclonal Antibody Therapy in Pregnant Women with Mild to Moderate COVID-19. Obstet Gynecol. 2022;139(4):616-8. doi: 10.1097/aog.0000000000004700
- Адамян Л.В., Вечорко В.И., Конышева О.В., Харченко Э.И. Беременность и COVID-19: актуальные вопросы (обзор литературы). Проблемы репродукции. 2021;27(3):70-7 [Adamian LV, Vechorko VI, Konysheva OV, Kharchenko EI. Beremennost' i COVID-19: aktual'nye voprosy (obzor literatury). Problemy reproduktsii. 2021;27(3):70-7 (in Russian)].